Alan Forrest Memorial Fund

Alan Forrest.

Named after a longtime faculty member, this fund will provide research support for PharmD students.

Dr. Alan Forrest was a faculty member and research professor in the School of Pharmacy and Pharmaceutical Sciences. He was renowned in the field of antimicrobial pharmacokinetics, pharmacodynamics and toxicodynamics (PK/PD/TD), and served as a researcher and educator for almost 40 years before he passed away in 2018.

This fund is designed to create an endowed research scholarship for students in UB’s doctor of pharmacy (PharmD) program.

During his career, Dr. Forrest held a number of prestigious faculty positions at UB, worked as the Senior Director of Pharmacometrics at the Institute for Clinical Pharmacodynamics, and was also an expert adviser to the Food and Drug Administration and the pharmaceutical industry.

His research primarily focused on aspects of translational medicine within the fields of anti-infectives and oncology. As a result of his work, exposure response analyses for antimicrobials have become standard practice in translational drug development.

In addition to mentoring more than 100 trainees and fellows, Dr. Forrest received numerous awards, and always maintained his focus on improving the care of patients.

Other Pharmacy and Pharmaceutical Sciences Funds

News from School of Pharmacy and Pharmaceutical Sciences

  • Gniazdowski selected for 2023-24 NACUBO Emerging Leaders Program
    10/11/23
    Kristin Gniazdowski, EdM, senior assistant dean, Finance and Administration, University at Buffalo (UB) School of Pharmacy and Pharmaceutical Sciences (SPPS) has been selected by the National Association of College and University Business Officers (NACUBO) for the 2023–24 Emerging Leaders Program.
  • Meaney named a 2023 Outstanding Reviewer for ACCP’s Pharmacotherapy Journal
    10/6/23
    Calvin Meaney, PharmD, clinical associate professor and interim division head, Division of Outcomes and Practice Advancement, Department of Pharmacy Practice, has been named a 2023 Outstanding Reviewer for the American College of Clinical Pharmacy’s (ACCP) Pharmacotherapy Journal.
  • Daly and Jacobs awarded national grant to lead review of community pharmacy practice transformation to advance patient care programs
    2/14/23
    Christopher Daly, PharmD, MBA, clinical assistant professor, Department of Pharmacy Practice, and David Jacobs, PharmD, PhD, assistant professor, Department of Pharmacy Practice, have received funding from the Community Pharmacy Foundation (CPF), an organization advancing pharmacy practice and patient care delivery through grant funding and resource sharing, to study national best practices for partnerships between payors and clinically integrated networks of community pharmacies to advance patient care program implementation and evaluation. 
  • UB CIGBS nominated for award honoring innovators in life sciences
    8/21/23
    UB’s Center for Integrated Global Biomedical Sciences (CIGBS) has been nominated for a 2023 Prix Galien USA award in the “Incubators, Accelerators and Equity” category.
  • Sprowl receives ASPET Division for Translational and Clinical Pharmacology Early Career Award
    2/1/23
    Jason Sprowl, PhD, assistant professor of pharmaceutical sciences, has received a 2023 Division for Translational and Clinical Pharmacology Early Career Award from The American Society for Pharmacology and Experimental Therapeutics (ASPET).
  • Bies appointed associate dean for Graduate Education
    9/20/23
    Robert Bies, PharmD, PhD, professor, Department of Pharmaceutical Sciences, has been appointed associate dean for Graduate Education, effective September 1.
  • Woodruff elected Chair-elect AACP Technology in Pharmacy Education and Learning Special Interest Group
    5/3/23
    Ashley Woodruff, PharmD, director of Interprofessional Education and clinical associate professor, Department of Pharmacy Practice, has been elected Chair-elect of the American Association of Colleges of Pharmacy (AACP) Technology in Pharmacy Education and Learning Special Interest Group (TIPEL SIG) where she will serve a three-year term.